| Trial ID: | L1324 |
| Source ID: | NCT00686751
|
| Associated Drug: |
Paricalcitol
|
| Title: |
Immune Effects of Vitamin D in Hemodialysis Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End Stage Renal Disease|Hemodialysis|Inflammatory Response|Cardiovascular Disease
|
| Interventions: |
DRUG: paricalcitol
|
| Outcome Measures: |
Primary: measurement of pro- and anti-inflammatory cytokines and inflammatory markers, first and second HD treatments for the 4 weeks of the study | Secondary: serum calcium level, 24 hours after termination of second HD treatment in week 3 of study|serum phosphate level, 24 hours after termination of second HD treatment in week 3 of study
|
| Sponsor/Collaborators: |
Sponsor: Renal Research Institute | Collaborators: Abbott
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
20
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: PREVENTION
|
| Start Date: |
2004-12
|
| Completion Date: |
2007-09
|
| Results First Posted: |
|
| Last Update Posted: |
2009-05-13
|
| Locations: |
Irving Place Dialysis Center, New York, New York, 10003, United States|Upper Manhattan Dialysis Center, New York, New York, 10025, United States|Yorkville Dialysis Center, New York, New York, 10128, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00686751
|
